Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.
Fiche publication
Date publication
février 2019
Journal
Breast cancer research and treatment
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles
Tous les auteurs :
de Nonneville A, Jauffret C, Gonçalves A, Classe JM, Cohen M, Reyal F, Mazouni C, Chauvet MP, Chopin N, Colombo PE, Jouve E, Darai E, Rouzier R, Coutant C, Gimbergues P, Azuar AS, de Lara CT, Lambaudie E, Houvenaeghel G
Lien Pubmed
Résumé
Invasive lobular carcinomas (ILCs) represent approximately 10% of all breast cancers. Despite this high frequency, benefit of adjuvant chemotherapy (CT) is still unclear.
Mots clés
Adjuvant chemotherapy, Breast cancer, Hormone receptor-positive, Lobular
Référence
Breast Cancer Res. Treat.. 2019 Feb 13;: